361 related articles for article (PubMed ID: 17588407)
1. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer.
Lee PC; Port JL; Korst RJ; Liss Y; Meherally DN; Altorki NK
Ann Thorac Surg; 2007 Jul; 84(1):177-81. PubMed ID: 17588407
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
[TBL] [Abstract][Full Text] [Related]
3. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA.
Annema JT; Hoekstra OS; Smit EF; Veseliç M; Versteegh MI; Rabe KF
Lung Cancer; 2004 Apr; 44(1):53-60. PubMed ID: 15013583
[TBL] [Abstract][Full Text] [Related]
4. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study.
Cerfolio RJ; Bryant AS; Ojha B
J Thorac Cardiovasc Surg; 2006 Jun; 131(6):1229-35. PubMed ID: 16733150
[TBL] [Abstract][Full Text] [Related]
5. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer.
von Haag DW; Follette DM; Roberts PF; Shelton D; Segel LD; Taylor TM
J Surg Res; 2002 Apr; 103(2):160-4. PubMed ID: 11922730
[TBL] [Abstract][Full Text] [Related]
6. Comparison of integrated positron emission tomography/computed tomography and mediastinoscopy in mediastinal staging of non-small cell lung cancer: analysis of 212 patients.
Iskender I; Kapicibasi HO; Kadioglu SZ; Sevilgen G; Tezel C; Kosar' A; Atasalihi A; Kir A
Acta Chir Belg; 2012; 112(3):219-25. PubMed ID: 22808763
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of advantages of positron emission tomography over computed tomography for N-staging in lung cancer patients.
Ebihara A; Nomori H; Watanabe K; Ohtsuka T; Naruke T; Uno K; Kuwahira I; Eguchi K
Jpn J Clin Oncol; 2006 Nov; 36(11):694-8. PubMed ID: 17068084
[TBL] [Abstract][Full Text] [Related]
8. Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
Gao SJ; Kim AW; Puchalski JT; Bramley K; Detterbeck FC; Boffa DJ; Decker RH
Lung Cancer; 2017 Jul; 109():36-41. PubMed ID: 28577947
[TBL] [Abstract][Full Text] [Related]
9. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.
D'Cunha J; Herndon JE; Herzan DL; Patterson GA; Kohman LJ; Harpole DH; Kernstine KH; Kern JA; Green MR; Maddaus MA; Kratzke RA;
Lung Cancer; 2005 May; 48(2):241-6. PubMed ID: 15829324
[TBL] [Abstract][Full Text] [Related]
10. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?
Casiraghi M; Travaini LL; Maisonneuve P; Tessitore A; Brambilla D; Agoglia BG; Guarize J; Spaggiari L
Eur J Cardiothorac Surg; 2011 Apr; 39(4):e38-43. PubMed ID: 21242094
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET/CT imaging in assessing mucin-producing non-small cell lung cancer with pathologic correlation.
Shim SS; Han J
Ann Nucl Med; 2010 Jun; 24(5):357-62. PubMed ID: 20306161
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of primary tumor FDG uptake for occult mediastinal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer.
Trister AD; Pryma DA; Xanthopoulos E; Kucharczuk J; Sterman D; Rengan R
Am J Clin Oncol; 2014 Apr; 37(2):135-9. PubMed ID: 23111361
[TBL] [Abstract][Full Text] [Related]
14. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2008 Aug; 86(2):362-6; discussion 366-7. PubMed ID: 18640297
[TBL] [Abstract][Full Text] [Related]
15. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue.
Chung MK; Jeong HS; Son YI; So YK; Park GY; Choi JY; Hyun SH; Kim HJ; Ko YH; Baek CH
Ann Surg Oncol; 2009 Nov; 16(11):3111-7. PubMed ID: 19609618
[TBL] [Abstract][Full Text] [Related]
16. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.
De Leyn P; Lardinois D; Van Schil PE; Rami-Porta R; Passlick B; Zielinski M; Waller DA; Lerut T; Weder W
Eur J Cardiothorac Surg; 2007 Jul; 32(1):1-8. PubMed ID: 17448671
[TBL] [Abstract][Full Text] [Related]
17. Survival of patients with true pathologic stage I non-small cell lung cancer.
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2009 Sep; 88(3):917-22; discussion 922-3. PubMed ID: 19699920
[TBL] [Abstract][Full Text] [Related]
18. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
[TBL] [Abstract][Full Text] [Related]
19. [Multimodal treatment of non small cell lung cancer].
Stoelben E; Digel W; Henke M; Passlick B
Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
[TBL] [Abstract][Full Text] [Related]
20. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
